12
Participants
Start Date
December 7, 2022
Primary Completion Date
May 5, 2023
Study Completion Date
May 5, 2023
Brodalumab
Solution for subcutaneous injection.
Ustekinumab
Solution for subcutaneous injection.
Placebo
The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
LEO Pharma Investigational Site, Brussels
LEO Pharma Investigational Site, Debrecen
LEO Pharma Investigational Site, Orosháza
LEO Pharma Investigational Site, Granada
LEO Pharma Investigational Site, Piraeus
LEO Pharma Investigational Site, Hamburg
LEO Pharma Investigational Site, Hamburg
LEO Pharma Investigational Site, Lübeck
LEO Pharma Investigational Site, Brescia
LEO Pharma Investigational Site, Madrid
LEO Pharma Investigational Site, Toulouse
LEO Pharma Investigational Site, Padua
LEO Pharma Investigational Site, Pontevedra
LEO Pharma Investigational Site, Essen
LEO Pharma Investigational Site, Valencia
LEO Pharma Investigational Site, Münster
LEO Pharma Investigational Site, Bad Bentheim
LEO Pharma Investigational Site, Thessaloniki
LEO Pharm Investigational Site, Mainz
LEO Pharma Investigational Site, Frankfurt
LEO Pharma Investigational Site, Napoli
LEO Pharma Investigational Site, Langenau
LEO Pharma Investigational Site, Liège
LEO Pharma Investigational Site, Athens
LEO Pharma Investigational Site, Iwonicz-Zdrój
LEO Pharma Investigational Site, Lodz
LEO Pharma Investigational Site, Poznan
LEO Pharma Investigational Site, Skierniewice
LEO Pharma Investigational Site, Warsaw
LEO Pharma Investigational Site, Warsaw
LEO Pharma Investigational Site, Wroclaw
LEO Pharma Investigational Site, Wroclaw
LEO Pharma Investigational Site, Wroclaw
LEO Pharma Investigational Site, Alicante
LEO Pharma Investigational Site, Barcelona
Lead Sponsor
LEO Pharma
INDUSTRY